Since Cs-A is a canonical drug recommended by “Asian-Pacific clinical practice guidelines” on the management of hepatitis B, in the future study, we will further investigate whether Cs-A can inhibit the Ct-HBx- NFATC2-TXNIP axis to suppress HCC progression. This evidence concerns the gene NFATC2 and hepatocellular carcinoma.